Jon Stonehouse, BioCryst CEO

An­oth­er BioCryst Fac­tor D in­hibitor hits clin­i­cal de­lay two months af­ter first one dis­con­tin­ued

BioCryst’s most ad­vanced ex­per­i­men­tal drug in its cur­rent pipeline has hit a snag, the com­pa­ny said Tues­day as part of its Q4 re­port.

BCX10013, an oral Fac­tor D in­hibitor for the treat­ment of com­ple­ment-me­di­at­ed dis­eases, is fac­ing de­lays in a clin­i­cal pro­gram be­cause of “re­cent dose-re­lat­ed ob­ser­va­tions” in a non­clin­i­cal study, ac­cord­ing to BioCryst. The com­pa­ny didn’t say much more than that.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.